News headlines about Cascadian Therapeutics (NASDAQ:CASC) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cascadian Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.8657249877838 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
A number of research analysts have recently commented on the stock. Raymond James Financial lowered shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. BidaskClub raised shares of Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. ValuEngine raised shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research cut shares of Cascadian Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Three research analysts have rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $5.63.
Shares of Cascadian Therapeutics (NASDAQ:CASC) opened at $9.96 on Monday. The firm has a market cap of $503.58, a PE ratio of -7.43 and a beta of 3.95. Cascadian Therapeutics has a 52 week low of $3.18 and a 52 week high of $10.21.
Cascadian Therapeutics (NASDAQ:CASC) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.01. During the same quarter in the prior year, the firm earned ($0.09) EPS. equities analysts predict that Cascadian Therapeutics will post -1.27 EPS for the current fiscal year.
WARNING: This article was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/05/cascadian-therapeutics-casc-getting-somewhat-favorable-media-coverage-report-shows.html.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.